{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:25:56Z","timestamp":1769595956951,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Industry and Trade of the Russian Federation","award":["12411.1008799.13.007"],"award-info":[{"award-number":["12411.1008799.13.007"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejps.2017.09.025","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T06:00:22Z","timestamp":1505800822000},"page":"631-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Development and pharmaceutical evaluation of the anticancer Anthrafuran\/Cavitron complex, a prototypic parenteral drug formulation"],"prefix":"10.1016","volume":"109","author":[{"given":"Helen M.","family":"Treshalina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir I.","family":"Romanenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry N.","family":"Kaluzhny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I.","family":"Treshalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksey A.","family":"Nikitin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander S.","family":"Tikhomirov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey E.","family":"Shchekotikhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejps.2017.09.025_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154278","article-title":"Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds: biological evaluation, characterization & molecular targets determination","volume":"11","author":"Ali","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2017.09.025_bb0010","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejps.2017.09.025_bb0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.ejps.2017.09.025_bb0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/14728222.2017.1310841","article-title":"The therapeutic potential of targeting ABC transporters to combat multi-drug resistance","volume":"21","author":"Bugde","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejps.2017.09.025_bb0030","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1016\/j.bmc.2016.09.071","article-title":"Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification","volume":"24","author":"Chen","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0035","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1021\/acs.jmedchem.5b00409","article-title":"Potent apoptotic response induced by chloroacetamidine anthrathiophenediones in bladder cancer cells","volume":"58","author":"Cogoi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/cr960371r","article-title":"The stability of cyclodextrin complexes in solution","volume":"97","author":"Connors","year":"1997","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2017.09.025_bb0045","first-page":"911","article-title":"Modulation of doxorubicin resistance in P388\/ADR cells by Ro44-5912, a tiapamil derivative","volume":"15","author":"De Jong","year":"1995","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2017.09.025_bb0050","first-page":"3595","article-title":"Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia","volume":"48","author":"Deffie","year":"1988","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejps.2017.09.025_bb0055","first-page":"309","article-title":"The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin","volume":"116","author":"Donenko","year":"1993","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ejps.2017.09.025_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/17460441.2013.798296","article-title":"Advances in the development of hybrid anticancer drugs","volume":"8","author":"Fortin","year":"2013","journal-title":"Expert Opin. Drug Discovery"},{"issue":"26","key":"10.1016\/j.ejps.2017.09.025_bb0065","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1021\/jacs.6b04339","article-title":"Streamlined total synthesis of uncialamycin and its application to the synthesis of designed analogues for biological investigations","volume":"138","author":"Gangwar","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.ejps.2017.09.025_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14656566.2016.1261109","article-title":"New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer","volume":"18","author":"Genova","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2017.09.025_bb0075","first-page":"2978","article-title":"Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia","volume":"46","author":"Goldenberg","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2017.09.025_bb0080","first-page":"25","volume":"55","year":"1980","journal-title":"NCI Monogr."},{"key":"10.1016\/j.ejps.2017.09.025_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejps.2017.09.025_bb0090","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI115154","article-title":"Reversal of daunorubicin resistance in P388\/ADR cells by itraconazole. Itraconazole and multidrug resistance","volume":"87","author":"Gupta","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"30","key":"10.1016\/j.ejps.2017.09.025_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.03.025","article-title":"Cancer chemoresistance; biochemical and molecular aspects: a brief overview","volume":"89","author":"Kachalaki","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0100","series-title":"Principles of Fluorescence Spectroscopy","volume":"954","author":"Lakowicz","year":"2006"},{"key":"10.1016\/j.ejps.2017.09.025_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.09.025_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jps.23077","article-title":"Cyclodextrins as functional excipients: methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10847-006-9247-2","article-title":"The complexation efficiency","volume":"57","author":"Loftsson","year":"2007","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0120","first-page":"263","article-title":"Nanoaggregation of inclusion complexes of glibenclamide with cyclodextrins. Int","volume":"519","author":"Lucio","year":"2017","journal-title":"J. Pharm."},{"key":"10.1016\/j.ejps.2017.09.025_bb0125","doi-asserted-by":"crossref","first-page":"38206","DOI":"10.1039\/C4RA06087C","article-title":"Binding interaction of a newly developed bisindole drug molecule with \u03b1-cyclodextrin: face to face shielding of indole hoops","volume":"4","author":"Mallick","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejps.2017.09.025_bb0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejps.2015.06.010","article-title":"Preparation and characterization of a new harmine-based antiproliferative compound in complex with cyclodextrin: increasing solubility while maintaining biological activity","volume":"77","author":"Meinguet","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejps.2016.09.029","article-title":"Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities","volume":"96","author":"Mohamed","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2017.09.025_bb0140","first-page":"293","article-title":"The evolution and adoption of standards used by AAALAC","volume":"51","author":"Newcomer","year":"2012","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"26","key":"10.1016\/j.ejps.2017.09.025_bb0145","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1021\/jacs.6b04339","article-title":"Streamlined total synthesis of uncialamycin and its application to the synthesis of designed analogues for biological investigations","volume":"138","author":"Nicolaou","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2017.09.025_bb0150","first-page":"385","article-title":"Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer","volume":"18","author":"Nourbakhsh","year":"2015","journal-title":"Iran J. Basic Med. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2017.09.025_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tips.2017.02.001","article-title":"A new view of pathway-driven drug resistance in tumor proliferation","volume":"38","author":"Nussinov","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0160","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/jps.10341","article-title":"When can cyclodextrins be considered for solubilizing purposes?","volume":"92","author":"Rao","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s10495-017-1375-1","article-title":"Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)","author":"Rathore","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejps.2017.09.025_bb0170","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ejmech.2014.09.021","article-title":"Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones","volume":"86","author":"Shchekotikhin","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejmech.2016.01.050","article-title":"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: optimization of synthesis and evaluation of antitumor properties","volume":"112","author":"Shchekotikhin","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0180","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/152581602753658637","article-title":"Multifactorial drug resistance: P-glycoprotein on the apex of the pyramyd","volume":"11","author":"Shtil","year":"2002","journal-title":"J. Hematother. Stem Cell Res."},{"key":"10.1016\/j.ejps.2017.09.025_bb0185","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1021\/acs.jmedchem.5b00460","volume":"58","author":"Soldi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2017.09.025_bb0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2017.09.025_bb0200","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejps.2016.09.032","article-title":"Hot-melt extrusion as a continuous manufacturing process to form ternary cyclodextrin inclusion complexes","volume":"96","author":"Thiry","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0205","doi-asserted-by":"crossref","first-page":"9522","DOI":"10.1021\/acs.jmedchem.5b00859","article-title":"Synthesis and characterization of 4,11-diaminoanthra[2,3-b]furan-5,10-diones: tumor cell apoptosis through tNOX-modulated NAD+\/NADH ratio and SIRT1","volume":"58","author":"Tikhomirov","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejps.2017.09.025_bb0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends - an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidem. Biomar."},{"key":"10.1016\/j.ejps.2017.09.025_bb0215","article-title":"Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug","author":"Vossen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.09.025_bb0220","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejps.2016.06.012","article-title":"Inclusion complexation with \u03b2-cyclodextrin derivatives alters photodynamic activity and biodistribution of meta-tetra(hydroxyphenyl)chlorine","volume":"95","author":"Yankovsky","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2017.09.025_bb0225","first-page":"2","article-title":"Anticancer drug development, getting out from bottleneck","volume":"2","author":"Yong","year":"2017","journal-title":"Int. J. Mol. Biol."},{"key":"10.1016\/j.ejps.2017.09.025_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2017.04.025","article-title":"Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance","volume":"135","author":"Zha","year":"2017","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T20:12:07Z","timestamp":1750882327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717305183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":44,"alternative-id":["S0928098717305183"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.09.025","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and pharmaceutical evaluation of the anticancer Anthrafuran\/Cavitron complex, a prototypic parenteral drug formulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}